GILD

#88
Gilead Sciences, Inc. - Common Stock
135.5 2 USD
-0.04%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
134.58
136.48
Faixa anual
104.46
157.27
Mudança diária
-0.04%
Mudança mensal
+5.91%
Mudança em 6 meses
+7.82%
Mudança anual
+21.41%
Fechamento anterior
135.5 8
Open
135.4 1
Mínimo
134.5 8
High
136.4 8
Volume
1 759
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas Dividendos
Trimestral Ano
  • Market Capitalization 168.26 B
  • Employee 17 K
  • Founded 1987
  • CEO Daniel O'Day
  • Website www.gilead.com
  • Headquarter Delaware, United States
  • FIGI BBG000CKGBP2
  • Industry Fabricantes de medicamentos - gerais
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
18.1
Índice preço/fluxo de caixa
5.23
Dividendos por ação
3.16
Rendimento de dividendos, %
2.57

Gilead Sciences, Inc. - Common Stock

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s.

Notícias